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Abstract Chemicals can elicit T-cell-mediated diseases
such as allergic contact dermatitis and adverse drug reac-
tions. Therefore, testing of chemicals, drugs and protein
allergens for hazard identification and risk assessment is
essential in regulatory toxicology. The seventh amendment
of the EU Cosmetics Directive now prohibits the testing of
cosmetic ingredients in mice, guinea pigs and other animal
species to assess their sensitizing potential. In addition, the
EU Chemicals Directive REACh requires the retesting of
more than 30,000 chemicals for different toxicological
endpoints, including sensitization, requiring vast numbers
of animals. Therefore, alternative methods are urgently
needed to eventually replace animal testing. Here, we
summarize the outcome of an expert meeting in Rome on
7 November 2009 on the development of T-cell-based
in vitro assays as tools in immunotoxicology to identify
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Abbreviations
ACD Allergic contact dermatitis
ADR Adverse drug reaction
APC Antigen presenting cell
BB Bandrowski’s base
DC Dendritic cell
DNCB 2,4-Dinitrochlorobenzene
FITC Fluorescein isothiocyanate
HSA Human serum albumin
ICS Intracellular cytokine staining
LC Langerhans cell
LLNA Local lymph node assay
LTT Lymphocyte transformation test
moDC Monocyte-derived dendritic cell
PBMC Peripheral blood mononuclear cells
PPD Para-phenylenediamine
TNBS 2,4,6-Trinitrobenzene sulphonic acid
Treg Regulatory T cell
Introduction
Replacement of animal testing: T cells as tools
in immunotoxicology
An expert meeting on ‘‘T cell recognition of chemicals,
protein allergens and drugs: towards the development of in
vitro assays’’, organized and chaired by Stefan F. Martin
and Andrea Cavani and the EU project Sens-it-iv, was held
on 7 November 2009, at the IDI-ICCRS in Rome. Partic-
ipants from clinical and academic institutions discussed the
state-of-the-art in order to promote further development of
T-cell-based in vitro assays for the identification and
detection of contact allergens, drugs and protein allergens.
The outcome of this meeting is reported here. In addition,
an overview of the efforts to induce chemical-specific T
cells in vitro from the early 1990s up to today is given.
Efforts to replace animal testing: background
Identification of the sensitization potential of chemicals is
mandatory to assure the safety of consumer products such
as cosmetics, and efforts are being made worldwide to
achieve this goal by the development of non-animal testing
strategies. The development of in vitro alternatives to
animal testing for the identification of contact allergens and
drugs that cause adverse reactions and of protein allergens
is necessary to reduce the large number of animals used in
toxicology for safety assessment. The seventh amendment
to the Cosmetics Directive of the European Union, which
has been in effect since March 2009, prohibits the use of
animals for sensitization testing of cosmetic ingredients
[1]. Thus, the gold standard used for the identification of
contact sensitizers, the local lymph node assay (LLNA)
[2, 3], can no longer be used. The EU Chemicals Directive
REACh would require a vast numbers of animals for
retesting of more than 30,000 chemicals to assess their
sensitizing potential [4–7]. International programmes have
been established for the development of in vitro alterna-
tives to animal testing in different areas of toxicology. In
February 2008, a coalition of US governmental agencies,
including the Environmental Protection Agency, the
National Toxicology Program and the National Institutes of
Health, signed a ‘‘Memorandum of Understanding’’ to
develop and implement new methods in order to cease
animal testing in the safety assessment of chemicals and
drugs over a time frame of about 10 years [8, 9]. The
National Research Council committee report proposed a
reasonable approach that includes in vivo testing in
genetically engineered animal models to fill the gaps in
knowledge [8, 10]. This approach to future strategies in
toxicology would enable cross-fertilization between the
areas of basic science and non-animal testing that would
result in a stepwise refinement of existing assays and
development of new assays leading to a reduction and
replacement of animal testing.
Traditionally, inherent toxicity of chemicals and drugs
have been identified and characterized by injecting or
gavaging compounds of interest into live animals and
monitoring whether they are harmed or not. These in vivo
assessment procedures are expensive, are time- and animal-
consuming, are usually ethically questionable, and afford
questionable results in terms of transferability to the human
system [10]. In the US it has been estimated that there are
about 10 million animals per year used in toxicity testing of
chemicals and drugs including mice, rats, guinea pigs and
other animals including dogs, cats and monkeys. In the EU,
the overall usage of animals in research, regulation and
diagnosis was about 12 million for the year 2005, of which
approximately 8% (1.03 million) were subjected to toxi-
cological safety studies sensu stricto [11].
These figures clearly demonstrate the need for alterna-
tives to whole-animal testing considering the steadily
growing number of new chemicals and drugs to be assessed
for their potential adverse effects on human health. Although
the US consortium aims at testing thousands of compounds
in high-throughput formats by applying biochemical and
human cell-based assays in conjunction with dose–response
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and extrapolation models, assessment of simple toxicity
endpoints such as cytotoxicity, altered protein expression or
DNA damage, along with computational toxicology (e.g.
quantitative structure–activity relationships), mainly
addresses acute adverse effects observed in single-dose
testing, rather than subchronic or chronic toxicity. Overall,
the replacement or refinement of in vivo acute toxicity test-
ing is in pretty good shape due to extreme efforts in the past
decades resulting in the establishment of a battery of alter-
natives accepted by the OECD and EU [10, 12–14]. So there
are a number of in vitro methods and validated guidelines
that allow the testing of dermal absorption, phototoxicity,
skin irritation, skin and eye corrosion, acute oral toxicity and
molecular endpoints such as mutagenicity. By contrast,
reliable repeated-dose toxicity testing, that is detection of
subchronic or chronic adverse effects, including endpoints
such as allergenicity, carcinogenicity or teratogenicity, has
so far turned out to be by far too complex to provide
appropriately simple measurements in the test tube. Unfor-
tunately, exactly these endpoints of repeated-dose toxicity
are expected to require increasing numbers of animals in all
industrial nations in the years to come.
In the context of the new EU Chemicals Directive REACh
[15], there are estimates that about 40–50 million additional
animals may be required to fulfil all related obligations for
toxicological characterization and risk assessment of the so-
called ‘‘existing chemicals’’ that entered the market before
1981 without appropriate safety evaluation prior to release.
So, all of these chemicals, certainly far more than 30,000,
need soon to be tested in a battery of assays mainly
addressing subchronic and chronic endpoints, as well as their
potency to induce sensitization and allergic contact derma-
titis (ACD). In the characterization of adverse effects on the
skin due to genotoxicity and sensitization, animal experi-
ments still predominate. Currently, in the EU about 60,000
animals per year suffer in the testing of the sensitizing or
irritating activities of chemicals alone (e.g. 22,184 guinea
pigs and 21,350 mice in 2005). In response to the imple-
mentation of REACh, these numbers might considerably
increase due to the lack of well-characterized and validated
in vitro models for measuring a chemical’s inherent aller-
genicity. Since established assays for evaluating this
toxicological endpoint are extremely expensive, time-con-
suming and, most notably, painful for the creature treated,
considerable effort is being applied to the development and
validation of appropriate in vitro methods for sensitization
testing, as explained in more detail below.
T-cell assays for the identification of contact allergens,
hazardous drugs and protein allergens
Triggering of T-cell responses to chemicals, drugs and
protein allergens is the key event that decides whether
initial sensitization that results in transient inflammation in
the target organ will lead to manifest disease upon repeated
contact with the chemical. Since many of the chemicals that
we encounter everywhere in our daily life can cause T-cell-
mediated ACD, respiratory allergies or adverse drug reac-
tions (ADR), there is a long-standing, and recently
significantly growing interest in using T cells as tools in
immunotoxicology for the identification of chemicals that
cause such health risks. Other types of assays are in
development and include peptide reactivity and single cell-
based assays using, for example, human keratinocytes and
dendritic cells (DC). They assess the activation of the innate
immune system and of the antioxidant response which are
hallmarks of the reactivity of such chemicals [16–23]. The
innate immune response is essential for both the sensitiza-
tion to the chemical and the subsequent adaptive T-cell-
mediated immune response upon further contacts [18–20].
In the single cell-based assays the sensitization potential of
chemicals is tested by measuring, for example, chemical-
induced antioxidant responses [21, 22] or IL-18 production
in keratinocytes [23] or the induction of activation markers
such as CD86 on the cell surface of DC [16, 17].
Since T cells are the pathogenic effector cells in
chemical-induced ACD, respiratory allergies or ADR,
T-cell-based in vitro assays may be very useful to identify
contact and respiratory allergens as well as hazardous
drugs. They can be easily incorporated into tiered risk
assessment strategies [16]. Protein-reactive small chemi-
cals efficiently induce T-cell responses and B-cell
responses, but the role of antibodies in the pathogenesis of
ACD and ADR is not clear and is a matter of controversy.
Therefore, assays based on B-cell responses to chemicals
have not been developed. T-cell epitopes are generated
efficiently via processing of chemically modified proteins
by antigen-presenting cells (APC) such as DC to produce
chemically modified peptides presented on MHC mole-
cules to T cells or by direct modification of MHC-bound
peptides. Our molecular understanding of the interaction of
the T-cell receptor (TCR) with chemicals presented in the
context of MHC molecules has significantly increased [24–
26]. We now know that some protein-reactive organic
chemicals, classical haptens, are recognized by T cells as
covalently hapten-modified MHC-bound peptides [27–32].
In contrast, metal ions such as nickel form noncovalent
complexes with amino acids such as histidine in both MHC
molecules and the TCR, sometimes also involving histidine
residues in the peptide that is bound to the MHC molecule
[33, 34]. Furthermore, some organic chemicals may be
recognized especially by effector and memory T cells
without covalent binding to carrier peptides on MHC as
formulated in the p-i concept (Fig. 1) [35–39].
T-cell-based in vitro assays should recapitulate key ele-
ments of the much more complex in vivo events that happen
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in the draining lymph nodes when DC that have been
activated in the skin have immigrated and present chemicals
to naive T cells. At present, the different protocols for in
vitro assays completely neglect important aspects of the in
vivo response to allergens that may contribute to allergenic
potency. Among these are the efficiency of skin penetration,
the metabolic capacity of skin cells to inactivate reactive
chemicals or to generate reactive adducts from nonreactive
chemicals, and the strength of chemical reactivity towards
proteins. The latter point is not addressed, for example,
when haptenated proteins are used as T-cell antigens.
However, chemical reactivity seems to correlate with
allergenic potency [40, 41]. Therefore, it is absolutely
crucial to know the questions that can be addressed by the
type of T-cell assay used (Table 1).
As for other, necessarily reductionist in vitro assays, a
positive result in an in vitro T-cell assay with a given
chemical does not necessarily mean that this chemical will
elicit a pathogenic T-cell response in vivo. Nevertheless, a
positive result is a clear indication of a potential risk
associated with the test compound due to its ability to
prime T cells that may cause ACD, respiratory allergies
or ADR. Therefore, T-cell assays should significantly
contribute to the refinement, reduction and eventual
replacement of animal testing in this field of immunotox-
icology and immunopharmacology.
The in vivo complexity of chemical-induced diseases as
addressed in animal testing strategies has never been fully
reproduced by currently available and developing in vitro
testing strategies in toxicology. However, legislation
requires the refinement, reduction and replacement of
animal testing. Therefore, this problem can only be solved
by continuous progress made in basic research using, for
example, the contact hypersensitivity model [18–20, 24] to
improve our still very incomplete understanding of the
immunological pathomechanisms. From this research we
have already identified and will identify key mechanisms
and pathways that are being successfully incorporated in
novel in vitro assays in immunotoxicology [17]. This will
help to build a tiered strategy with a battery of assays that
cover the different steps from sensitization to elicitation of
chemical-induced disease [16, 17].
α β α β α β
Non-covalent binding (p-i concept)
α β
haptens
contact allergens, drugs
etc.
α β α β
metal ions
nickel, cobalt etc.
some drugs
sulfamethoxazole etc.
peptide dependent peptide independent
complex formationcovalent binding
peptide independentpeptide dependent
TCR bindingMHC binding
Fig. 1 Modes of chemical recognition by T cells. T cells interact
with their TCR with MHC class I or class II molecules that present
chemicals covalently bound to peptides in the binding groove of the
MHC molecules (classical haptens), complexed to amino acids in
MHC molecules and TCR with or without participation of MHC-
bound peptides (metal ions) or noncovalently associated with MHC
and/or TCR in a peptide-dependent or -independent manner (p-i
concept, some drugs)
Table 1 Testable parameters
addressed in T-cell assays
Skin
penetration
Chemical
reactivity
Innate immune
activation
T-cell
response
Contact dermatitis ?? ?? ?? ??
In vitro assays
Direct addition -- ?? ? ??
APC modification -- ?? ? ??
Self-protein conjugates -- -- -- ??
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Past efforts using T cells in the study of immune
responses to chemicals
In the 1990s the molecular basis for T-cell recognition of
chemicals became clear [24–26]. Efforts were made to
study primary human T-cell responses to chemicals. Dif-
ferent approaches were taken to induce T-cell responses to
chemicals with respect to the populations of T cells and
APC used, the means of application of the test chemicals
and the cell culture protocols and readouts [42–51].
Table 2 summarizes the studies that have used protocols
for priming of naive T cells with chemicals applied as
shown in Fig. 2 and studies that have tested haptenated
self-proteins as antigens for T-cell lines and clones from
allergic patients [52–54]. Most protocols have used hapten-
modified DC as APC and naive T cells as responder cells.
Readout systems were T-cell proliferation and cytokine
production. These studies demonstrated that it is possible to
detect T-cell responses to chemicals in the naive repertoire,
especially in the case of strong contact allergens such as
2,4,6-trinitrochlorobenzene (TNCB) that was mostly used
in the form of the water-soluble derivative 2,4,6-trinitro-
benzene sulphonic acid (TNBS) to directly modify APC.
Moreover, they showed that memory T-cell responses can
be analysed as well.
State-of-the-art of T-cell assays
Due to the scientific and technological developments in
recent years, T-cell-based in vitro assays have improved. It
is now possible to isolate highly pure and defined T-cell
and APC populations by flow cytometric or magnetic bead
separation technologies. Cytokines have been identified
that upon addition to in vitro cultures help optimize T-cell
responses. Improved protocols for the generation of dif-
ferent types and large numbers of DC have been developed
and the knowledge of innate immune signals allows mat-
uration and activation of DC in a suitable manner. Most
protocols nowadays use monocyte-derived DC as APC and
purified naive T cells as responder cells. This excludes the
presence of natural CD4?CD25?FOXP3? regulatory T
cells (Treg) which may limit the extent of T-cell responses
and prevent detection of responses to weakly immunogenic
allergens or drugs [55]. Thus, the removal of Treg may
significantly increase assay sensitivity [50].
Currently used readout systems are T-cell proliferation
systems that use radioactive labelling or dilution of flu-
orochromes such as carboxyfluorescein succinimidyl ester.
Moreover, T-cell activation markers have been identified
that may be used to identify antigen-activated T cells.
Examples are the TNF receptor family member CD137
(4-1BB) and the costimulatory molecule CD154 (CD40
ligand) which are induced specifically in antigen-activated
T cells and upregulated de novo on the cell surface [56–
58]. This allows the detection and isolation of antigen-
activated T cells. In addition, techniques are now available
that allow the detection of secreted or intracellular cyto-
kines. The pairing of new laser technologies with new
fluorochromes has led to the possibility of using multipa-
rameter flow cytometry for the analysis of chemical-
triggered T-cell responses at the single-cell level [51].
The method of antigen delivery to T-cell assays is a
critical point. Test chemicals can be added either directly to
the assays or they can be used to modify APC or are added
as hapten–protein conjugates (Fig. 2). These strategies are
used to simulate the different effects of chemicals when
they enter target tissues in vivo. Thus, chemical contact
with the skin will result in direct interaction of the chem-
icals with cells. This will lead to the modification of
membrane proteins on the cell surface and of intracellular
proteins, and also to the direct modification of MHC-bound
peptides. In addition, extracellular proteins will be modi-
fied to produce antigenic T-cell determinants when the
haptenated proteins are taken up and processed by APC
[19, 24].
The direct addition of chemicals to T-cell assays or the
direct modification of APC can rarely be controlled with
respect to the efficiency of chemical binding to cellular or
extracellular proteins, the essential prerequisite for the
induction of T-cell priming. In some cases there are hap-
ten-specific antibodies that allow testing of productive cell
surface modifications implicating the formation of T-cell
epitopes. Without knowing whether a chemical has reacted
with cellular or extracellular proteins, only a positive T-cell
response is informative while a negative result cannot be
interpreted. The latter may be caused by the failure of the
chemical to react with proteins under in vitro culture
conditions resulting in its inability to generate T-cell epi-
topes, or it may be due to the lack of T cells in the human
or the individual donor’s T-cell repertoire with specificity
for that chemical. Therefore, the use of quality-controlled
hapten–protein conjugates as antigens in T-cell assays has
some advantages. The production of such conjugates
requires that the chemical of interest binds covalently to or
forms sufficiently stable complexes with a carrier protein.
The reaction conditions can be adjusted to allow efficient
coupling and adduct formation can be controlled by mass
spectrometry. Ideally the carrier protein is a self-protein
with absent or low immunogenicity.
Human serum albumin (HSA) is one of the carriers used
in T-cell assays (Table 2). It is found in high concentra-
tions in serum and in tissues such as skin. Hapten–protein
conjugates must be taken up by APC and processed to
hapten-modified peptides that can bind to MHC molecules.
For the priming of CD8? T cells the APC must be able to
cross-present the hapten-modified peptides on MHC class I
T cell assays in immunotoxicology 4175
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molecules [59]. The production of such hapten–protein
conjugates requires sufficient knowledge of the chemistry
of the test compound. Buffer, pH, and the molar ratios of
chemical and protein are some of the factors that must be
considered. The protein coupling and the degree of protein
haptenation can be monitored using mass spectrometry.
Here the mass shifts that are caused by chemical binding
can be calculated by detection of adducts. Semiquantitative
analysis yields information on the coupling efficiency [51,
54, 60, 61].
It has to be born in mind that the DC are activated in
vivo in the tissue, for example the skin, directly by the
protein-reactive chemical or indirectly by chemical-
induced danger signals. In the latter case these signals can
be derived from other tissue cells or from the extracellular
matrix [18, 19, 62] with the consequence that this part of
the immune response is missing in in vitro assays. There-
fore, appropriate DC activation may be required for
efficient in vitro priming of naive T cells (Table 1). In
particular, when using hapten–protein conjugates, these
signals are not given. Moreover, some of the chemical-
induced responses cannot be recapitulated in vitro due to
tissue-derived danger signals [18, 19, 62]. Therefore, for
optimal T-cell responses it may be crucial to provide these
innate immune signals by adding proinflammatory cyto-
kines such as TNF-a or ligands for Toll-like receptors such
as lipopolysaccharide. One also has to consider that the
timing and dosing of DC stimulation and antigen addition
are critical with respect to the different capacities of
immature versus mature DC to take up exogenous proteins
such as hapten–protein conjugates.
Currently, two basic methods are used to prime naive
human T cells with chemicals, drugs or protein allergens.
The coculture of APC and T cells in the in vitro T-cell
priming assay with chemicals induces primary T-cell
responses and the readout of secondary responses by
restimulation with other control chemicals is used to ensure
that antigen-specific T cells were primed (Fig. 3). A second
method, the T-cell amplification method, introduces a
primary polyclonal stimulation with a low starting number
of T cells [63]. The idea is to amplify a low number of
antigen-specific precursor T cells by polyclonal expansion
several thousand fold and then interrogate this amplified
T-cell pool by stimulation with the antigen of interest for
antigen-specific T cells. While the former approach works
with chemicals, the latter assay is reliable as readout for
protein allergens. It allows determination of frequencies of
antigen-specific T cells, both in the naive and the effector/
memory T cell pool. It remains to be tested whether this
amplification method will work with hapten–protein
conjugates.
Meeting presentations
Topic 1: chemical-reactive T cells
Philipp Esser (Freiburg) and Sonja Schmucker (Bergisch-
Gladbach) presented the Sens-it-iv approach using the in
vitro T-cell priming assay. Here, immature moDC are used
to prime sorted naive T cells. It has been possible to prime
naive human T cells with directly modified APC using
TNBS and dinitrobenzene sulphonic acid. Proliferative
responses were contact allergen-specific as demonstrated
in secondary restimulations with haptenated DC. These
Cl
addition to culture hapten-modification of DC hapten-protein conjugates
Fig. 2 Modes of chemical delivery in T-cell assays. Chemicals that
are used to stimulate T cells in T-cell assays can be either added
directly or used to modify APC such as DC (hapten modification).
Alternatively, chemical-coupled proteins (hapten–protein conjugates)
such as HSA can be added to the T-cell/DC cocultures
Naive T cells
iDC + chemical 
component
Detection
- IFN-γ +cells
- Proliferation
iDC
generation
-7day 0 5 10/11
- Proliferation
+
Fig. 3 Schematic protocol for in vitro T-cell priming assays. In the in
vitro T-cell priming assay, sorted naive human T cells are primed
with immature DC plus chemical. Proliferation can be measured on
days 5 and 10. The culture is restimulated with fresh DC plus
chemical on day 10 to assess antigen-specificity and to perform
additional functional testing such as cytokine secretion assays or
intracellular cytokine staining (ICS)
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results are also confirmed by the analysis of intracellular or
secreted IFN-c by flow cytometry. The latter approach
allows the detection and frequency analysis of antigen-
specific CD4? and CD8? T cells at the single-cell level. In
addition, naive human T cells were primed with 2,4-dini-
trophenyl-modified HSA fed to immature moDC that were
then activated with the Toll-like receptor-4 agonist lipo-
polysaccharide [51]. Andrea Cavani (Rome) presented
similar results obtained in the Sens-it-iv project. He showed
that both direct conjugation of APC (mostly immature DC),
and feeding APC with hapten–protein conjugates can
induce specific T-cell responses in vitro. However, there
are some limitations. In the case of chemicals directly
interacting with APC, toxicity, as measured by cell via-
bility, is a major issue that limits optimal antigen
concentrations with heavily lipophilic compounds. Most of
the current assays use a cell viability greater than 75–80%.
Sonication of such compounds may help with selective
chemicals such as squaric acid.
On the other hand, T-cell responsiveness to hapten–
protein conjugates varies depending on the methodology
used for the preparation of the conjugates, calling for strict
standardization. This issue was addressed by Hermann-
Josef Thierse (Mannheim) who showed how such hapten–
protein conjugates can be produced, and the importance of
physiologically related conditions such as pH, modifiable
amino acids and the type of chemical. He presented a mass
spectrometry-based immunoproteomic approach for the
identification of chemical modifications and outlined an
approach that allows the degree of hapten modification of
functionally active carrier proteins to be semiquantitatively
determined and the type and site of modification to be
identified [51]. Furthermore, interesting data were pre-
sented that were derived from this technology and modern
proteomics to identify physiologically relevant target pro-
teins that are hapten-modified in whole cells such as human
keratinocytes and DC as well as in the skin. Surprisingly,
only a limited number of proteins seem susceptible to
hapten modification. Among the identified proteins are
many that are associated with innate immune and stress
responses as well as with antigen processing such as heat
shock proteins [64–66]. Moreover, by applying recently
established quantitative proteomic technologies to human
skin cells, novel chemically regulated protein patterns have
been discovered, which also may support the development
of allergen-specific biomarkers in in vitro testing [64].
Marc Vocanson (Lyon) presented an alternative
approach, developed in collaboration with COLIPA, the
European trade association representing the interest of the
cosmetics, toiletry and perfumery industry. He showed that
cultivation of haptenated moDC with CD25? Treg-depleted
PBMC significantly increased hapten-specific T-cell prim-
ing against numerous contact allergens and, notably, weakly
immunogenic allergens [50]. This indicates that Treg
depletion increases the sensitivity of the assay. Thomas
Rustemeyer (Amsterdam) presented data on in vitro T-cell
priming by moDC. In this procedure moDC were also
incubated with different contact allergens and cultured with
autologous CD45RA? T cells in the presence of various
cytokine cocktails [47, 49]. After 10–14 days T cells were
divided into three aliquots and restimulated with medium
alone, with the allergen used for priming or with a non-
crossreacting or crossreacting contact allergen. Allergen-
specific proliferation and cytokine production (i.e. IFN-c and
IL-5) were found only in cultures restimulated with the
allergen used for priming or with crossreacting compounds.
In addition, loading of HLA A2?-MUTZ-3 cells with pep-
tide antigens allowed the induction of specific proliferation.
Matthias Peiser (Berlin) proposed the contact allergen-
activated T cell assay, a newly developed in vitro assay
that detects the sensitizing potency of chemicals via
DC-induced expression of lineage-specific T-cell transcrip-
tion factors. After coculturing allergen-stimulated DC from
the skin with T cells, polarization to specific subpopulations
is analysed by expression of T-bet/IFN-c, GATA3/IL-4,
RORC2/IL-17 and FOXP3/IL-10 (data unpublished).
The loose-fit coculture-based sensitization assay
(LCSA), developed by Reinhard Wanner (Berlin), is an
alternative method to the mandatory LLNA (OECD test
guideline 429) [14]. The sensitizing potential of chemicals
is estimated according to detection of the biomarkers
CD86, IL-6 and CCL4 by flow cytometry. This assay is
unique among those involving DC differentiation in that
the DC are generated from monocytes within a growing
layer of primary keratinocytes [67, 68]. A panel of chem-
icals have already been tested and the LCSA was able to
quantify the irritative and sensitizing potential within
5 days [69]. A comparison of half-maximal increases in
mean fluorescence intensity for CD86 demonstrated con-
cordance between the LCSA and LLNA for substances
such as DNCB and PPD, which are categorized as extreme
and strong, respectively. However, a few divergent classi-
fications may reflect method-intrinsic differences in
bioavailability between animal experiments (LLNA) and
the barrier-free in vitro test (LCSA). In contrast to LLNA,
the irritant sodium lauryl sulphate, weak sensitizers and
nickel were correctly detected by the LCSA.
Topic 2: drug-reactive T cells
Dean Naisbitt (Liverpool) presented data on the charac-
terization of antigenic determinants and the lessons learnt
from drug allergy. Drugs and chemicals are thought to
activate T cells by formation of reactive intermediates that
bind covalently to protein. The paucity of studies that
define protein adducts in patients has severely restricted
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mechanistic studies that relate chemistry to immune func-
tion. Thus, an improved understanding of T-cell responses
to drugs and chemicals and subsequently the development
of sensitive and specific T-cell assays to predict chemical
sensitization requires a multidisciplinary scientific
approach that relates compound distribution (including
protein conjugation) to immune function. To do this, it is
critical that tools are developed to define how haptens,
compounds that interact directly with proteins, form T-cell
stimulatory antigenic determinants. Several independent
research groups have attempted to develop T-cell assays
using soluble compounds, with limited success. The over-
riding problem is that the concentration required to achieve
an antigenic threshold is often associated with a decrease in
cell viability or loss of function. To overcome this issue,
haptens can be delivered in a conjugated form (associated
with either cellular or soluble protein). This approach has
resulted in encouraging but often inconsistent data, which
likely relates to the fact that methods to generate fully
quantified protein adducts do not exist. To generate an
antigenic determinant, one must consider absolute levels of
binding, the stability of adducts (not all covalent bonds are
irreversible) and the epitope profile (the number of site-
specific modifications).
Using state-of-the-art mass spectrometry and b-lactam
antibiotics as model haptens, the Liverpool group has
embarked upon a series of experiments to begin addressing
this problem. Semiquantitative epitope profiling has
revealed that b-lactams bind to a subset of lysine residues
on proteins in a dose- and time-dependent manner, and
display different preferences for the sites of modification.
In vivo modification of albumin from flucloxacillin-
exposed patients has also been observed, with multisite
modification being detected in each patient [70]. Repro-
ducible, lymphocyte proliferative responses are detectable
in allergic patients with drug-modified albumin, but only
when the number of modifications exceeds a threshold.
The relationship between protein adduct formation and
T-cell activation is even more complex with the drug
metabolite hapten nitrososulphamethoxazole. Five struc-
turally different protein adducts were characterized when
nitrososulphamethoxazole was incubated with two proteins
HSA and glutathione S-transferase p [71]. The involve-
ment of these complex and metastable haptenic structures
in the stimulation of T cells has not been studied.
It is also important that future T-cell assays utilize cells
from a large cohort of healthy volunteers. Recently, several
strong genetic associations have been identified between
expression of particular HLA molecules and susceptibility
to specific forms of drug allergy [72–74]. Leading on from
this, it was shown [75] that T-cell recognition of the
reverse-transcriptase inhibitor abacavir is uniquely restric-
ted by HLA-B*5701 and not closely related HLA
molecules. It is possible that strong sensitizing chemicals
such as the dinitro-halogenated benzenes overcome the
absolute requirement for HLA restriction by the formation
of multiple haptenic epitopes. However, this will not be the
case for weak sensitizers, where the distribution of adducts
formed will be more restricted.
Monika Keller (Bern) discussed strategies to improve in
vitro tests for the diagnosis of ADR and for the detection of
pre-existing sensitizations (risk assessment of drugs).
Antigen-specific T lymphocytes can be detected in PBMCs
by the measurement of proliferative responses (e.g.
[3H]thymidine incorporation, carboxyfluorescein succin-
imidyl ester staining), the upregulation of activation
markers (CD69, CD71, CD25, HLA-DR) and cytokine
secretion (ELISA, ELISPOT, intracellular staining, bead
assays), or by cytotoxicity assays.
The oldest test based on these principles is the ‘‘lym-
phocyte transformation/proliferation test’’ (LTT), which
has a high specificity for drug-induced allergic reactions,
but a poor sensitivity. It is suitable for testing different drug
classes, and is even used for routine testing in drug hyper-
sensitivities in some centres. But its practicability is limited
(cells need to be cultured for 7 days, it involves radioactive
labelling, human AB serum is the best culture additive, and
it needs technical experience). Alternative in vitro tests are
therefore of great interest. For CD69 upregulation, HSA can
be used instead of AB serum and cells need to be cultured
for only 2–3 days [76]. Alternatively, as used in several
studies, cytokines can be measured in the cell culture
supernatant: the determination of IL-5 in PBMCs from ten
patients with exanthema from amoxicillin showed a sensi-
tivity of 92% and a specificity of 100% [77]. In another
study, IFN-c was measured in 36 patients with cutaneous
drug reactions [78] and showed a sensitivity of 78%.
Lochmatter et al. [79] measured 17 cytokines and chemo-
kines in the cell culture supernatant using multiplex assays
in five patients allergic to amoxicillin, five patients allergic
to sulphonamides and five healthy controls. IL-2, IL-5,
IFN-c, IL-13 and TNF-a were increased most consistently
among the 17 cytokines/chemokines measured. Thus,
measuring different cytokines seems to improve the sensi-
tivity of the test. These studies were all performed in
patients with a clear history of ADR and positive LTTs or
positive skin tests. Prospective studies with a larger number
of patients and healthy controls are necessary to compare
the sensitivity and specificity of the LTT, and CD69 and
cytokine measurement.
The results of all in vitro tests are influenced by (a) the
in vitro reactivity of the antigen/drug, (b) the frequency of
drug-specific T cells, and (c) whether the reactive T cells
are being detected appropriately by the test system chosen.
The combination of different tests may increase the
sensitivity.
T cell assays in immunotoxicology 4179
The detection of drug-specific T cells of sensitized,
allergic patients is already a challenge and often fails. For
the in vitro risk assessment of drugs a test is needed that
detects the very low amount of pre-existing, i.e. naive, drug-
specific T cells in healthy, drug-unexposed individuals, as
currently developed for contact allergens. An improvement
in the methods for the identification of the presumably rare
drug-specific naive precursors is necessary. Preactivation of
lymphocytes with cytokines (e.g. IL-7, IL-15, IL-2), poly-
clonal preactivation (e.g. with PHA), the costimulation with
antibodies to costimulatory (anti-CD28, CD49d) or adhe-
sion molecules (ICAM-1), the removal of Treg cells, the
separate analysis of specific T-cell subsets, the use of DC as
APC, the generation of T-cell lines, or prolonged T-cell
cultures are only some ideas that might be evaluated. In
some preliminary experiments modifying the LTT or the
cytokine secretion experiments, it was possible to increase
the (memory) responses to recall antigens but not to induce
a naive T-cell response to small chemicals.
Enrico Maggi (Florence) discussed the potential use of
drug-coupled carrier proteins for testing of drug cross-
reactivities. He reported data on the in vitro activity of a
stable reagent formed by penicillin G active ester coupled
with HSA (pen-HSA) on the PBMC of patients with a
history of ADR to b-lactams (amoxicillin). In six (two with
immediate and four with delayed ADR) out of ten patients
this approach allowed the detection of a clinically manifest
cross-reactivity between penicillin and amoxicillin that was
not determined using the uncoupled drugs. The prolifera-
tive response to pen-HSA was HLA-restricted since it was
abrogated by anti-class II HLA monoclonal antibodies.
Notably, no proliferation was detectable with PBMC from
ten non-allergic donors in response to pen-HSA or to the
carrier alone. Thus, T-cell-based assays may also be of
relevance for diagnostic purposes, e.g. to predict antibiotic
cross-reactivities, and may allow a treatment regimen to be
adapted to avoid drug cross-reactivity.
Topic 3: protein allergens
Federica Sallusto (Bellinzona) presented the T-cell ampli-
fication method [63]. In this assay rare antigen-specific
precursor T cells from peripheral blood lymphocytes are
amplified in vitro by polyclonal stimulation in replicate
cultures. Each naive T cell is expanded several hundred- to
a thousand-fold to clonal T cell blasts. These cultures are
then stimulated with the antigen of interest allowing the
identification of antigen-specific cultures via measurement
of proliferation or cytokine production and, subsequently,
the production of T-cell lines, clones and T-cell libraries.
This method allows the assessment of the frequencies of
antigen-specific precursors as well as of the TCR repertoire
and has been used successfully with protein allergens. The
method also works with memory T cells. The assay will be
tested using for example HSA-coupled contact allergens
and drugs. It may be very useful to increase the sensitivity
of detection of T-cell responses especially in the case of
low numbers of precursor T cells in the naive T-cell pool
for a given chemical.
Future perspectives
The induction of a T-cell response by chemicals, drugs or
protein allergens is the crucial step for the manifestation of
allergic diseases and T-cell-mediated ADR. Therefore, it is
important to further pursue the improvement in our meth-
ods to use T cells as valuable tools in immunotoxicology.
Limitations are recognized and must be overcome where
possible. One of the most obvious advantages is the clear
distinction made by T cells between chemicals that form
T-cell epitopes such as contact allergens, and irritants that
cause toxic irritative inflammatory responses such as irri-
tant contact dermatitis. Single-cell assays often fail to
clearly differentiate between these types of chemicals due
to an overlap in the mechanisms by which they trigger
inflammation [80, 81].
One of the major drawbacks impeding the use of T-cell-
based assays as high through-put test systems is the need to
work with primary cells in an autologous setting. This causes
donor to donor variations and requires testing of a sufficient
number of different donors to yield statistically significant
results and to exclude false results that may in part be due to
differences in individual TCR repertoires. Moreover, the
different properties of test chemicals, including their reac-
tivity with proteins, toxicity and solubility, preclude in some
cases the direct addition to cultures. Hapten–protein conju-
gates can overcome some of these problems, but the
production of such quality-controlled reagents also prevents
high throughput testing. Nevertheless, the T-cell readout is
the ultimate test to predict allergenicity of chemicals or their
potential to induce T-cell-mediated ADR. Since it is not
likely that such assays will be a tool for the testing of large
numbers of chemicals, they may be used as part of a tiered
strategy [16] especially to test chemicals that fail to give
unambiguous results in single cell-based assays that address
innate immune mechanisms. Moreover, they can be used for
chemicals that are of great interest for the cosmetics or
pharmaceutical industry due to unique properties that are
needed for a certain product. With the current technology it
should then be possible to produce standardized hapten–
protein conjugates for testing purposes.
A very important point that is key to comparing data
obtained by different laboratories is the data evaluation.
Standardization of the assays, harmonization of protocols
and the definition of criteria for positive and negative
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results including suitable statistics is an urgent need. Per-
formance standards have to be defined and the results
obtained in the assays need to be compared with data from
a LLNA [82, 83] and with clinical experience with known
test compounds. A sufficient number of known compounds
have to be tested in a combined effort and ring trials will be
performed on a limited set of these compounds to assess
the robustness and transferability of the assay technology.
It remains to be seen whether such assays are suitable for
determining the allergenic potency as can be done with
the LLNA. Moreover, data reporting has not yet been
standardized, but establishing publication guidelines, as
recently proposed for T cell-based immune monitoring
strategies [84], will enable comparison of data from dif-
ferent laboratories.
The current problem is that the field is still in the
exploratory phase. Assays are still being refined, protocols
are being modified and new data from basic research are
being incorporated, one example being the identification of
new T-cell subsets and T-cell plasticity that impacts, for
example, on the cytokine readout [85]. Nevertheless, such
expert meetings should be held on a regular basis in the
future in order to achieve our goal. It is clear that knowl-
edge of the chemistry is required to perform and refine
T-cell-based assays, and that this involves close collabo-
rations with chemists possessing this expertise. Historical
data are available and more experience is gained with the
development of assays that are based on the chemical
reactivity to peptides [40, 41]. It remains an open and
difficult question whether and how T-cell-based assays can
incorporate pre- and pro-haptens [86, 87].
Conclusion
In summary, T-cell-based assays, despite their obvious
complexity and limitations, are a useful and valid tool in
immunotoxicology. They support predictive hazard iden-
tification and risk assessment and will complement other
assays that are based on single cells, e.g. DC or keratino-
cytes, and address the induction of innate immune
responses as measured, for example, by chemical-induced
cytokine production or expression of activation markers on
these cells [17]. The recent major improvements in the
T-cell assay protocols include the removal of immuno-
regulatory cells which significantly increases the sensitivity
of the assays [50]. This has been shown in mice where
contact hypersensitivity responses to weak contact aller-
gens were only induced when all CD4? T cells were
depleted before sensitization [88–90]. In addition sensitive
detection methods allow amplification of weak T-cell
responses by polyclonal expansion of precursors [63] and
the multiparametric analysis of single cells using flow
cytometric detection of cell surface markers including
those that indicate antigen-specific activation and intra-
cellular cytokines [51, 56–58]. These technologies allow
isolation of live antigen-specific cells for the generation of
T-cell clones and for the determination of frequencies of
allergen- and drug-specific T cells and of the diversity of
the TCR repertoire. Since T-cell assays address the adap-
tive immune response that is crucial for the development of
chemical-induced disease, they provide the ultimate answer
to the question whether an unknown chemical has the
potential to induce contact or respiratory allergies or ADR.
Thus, we are convinced that T-cell assays will contribute to
the efforts to reduce and eventually replace animal testing.
This is still a difficult task given that in vitro assays must
be able to guarantee the safety of consumer products and
drugs [91].
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